Bayer (FRA:BAYN) PT Set at €75.00 by The Goldman Sachs Group

The Goldman Sachs Group set a €75.00 ($88.24) price objective on Bayer (FRA:BAYN) in a research report sent to investors on Monday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.

BAYN has been the topic of several other research reports. Morgan Stanley set a €68.00 ($80.00) target price on Bayer and gave the stock a buy rating in a research report on Wednesday, October 21st. Berenberg Bank set a €76.00 ($89.41) price target on Bayer and gave the stock a buy rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. set a €77.00 ($90.59) price target on Bayer and gave the stock a neutral rating in a research report on Wednesday, October 21st. Sanford C. Bernstein set a €73.00 ($85.88) price target on Bayer and gave the stock a buy rating in a research report on Wednesday, October 7th. Finally, DZ Bank reaffirmed a buy rating on shares of Bayer in a research report on Monday, August 24th. Five analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of €73.38 ($86.32).

Shares of FRA BAYN opened at €40.79 ($47.98) on Monday. Bayer has a fifty-two week low of €91.58 ($107.74) and a fifty-two week high of €123.82 ($145.67). The stock’s 50-day simple moving average is €49.42 and its 200-day simple moving average is €57.81.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: Why Invest in Dividend Kings

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.